1. A prospective observational post‐marketing study of natalizumab‐treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. (12th June 2013) Authors: Outteryck, O.; Ongagna, J.C.; Brochet, B.; Rumbach, L.; Lebrun‐Frenay, C.; Debouverie, M.; Zéphir, H.; Ouallet, J.C.; Berger, E.; Cohen, M.; Pittion, S.; Laplaud, D.; Wiertlewski, S.; Cabre, P.; Pelletier, J.; Rico, A.; Defer, G.; Derache, N.; Camu, W.; Thouvenot, E. Journal: European journal of neurology Issue: Volume 21:Number 1(2014:Jan.) Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical follow‐up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real‐life cohort study. (3rd August 2018) Authors: Chartier, N.; Epstein, J.; Soudant, M.; Dahan, C.; Michaud, M.; Pittion‐Vouyovitch, S.; Guillemin, F.; Debouverie, M.; Mathey, G. Journal: European journal of neurology Issue: Volume 25:Number 12(2018) Page Start: 1439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Managing generalized interferon‐induced eruptions and the effectiveness of desensitization. Issue 5 (May 2014) Authors: Poreaux, C.; Bronowicki, J.‐P.; Debouverie, M.; Schmutz, J.‐L.; Waton, J.; Barbaud, A. Journal: Clinical & experimental allergy Issue: Volume 44:Issue 5(2014:May) Page Start: 756 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗